PMID- 36733607
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240102
IS  - 2366-3987 (Electronic)
IS  - 2366-3987 (Linking)
VI  - 6
IP  - 1
DP  - 2023 Jan
TI  - Cell-free, Dendritic Cell-mimicking Extracellular Blebs for Molecularly 
      Controlled Vaccination.
LID - 2200125 [pii]
LID - 10.1002/adtp.202200125 [doi]
AB  - Dendritic cells (DCs) are prime targets for vaccination and immunotherapy. 
      However, limited control over antigen presentation at a desired maturation status 
      in these plastic materials remains a fundamental challenge in efficiently 
      orchestrating a controlled immune response. DC-derived extracellular vesicles 
      (EVs) can overcome some of these issues, but have significant production 
      challenges. Herein, we employ a unique chemically-induced method for production 
      of DC-derived extracellular blebs (DC-EBs) that overcome the barriers of DC and 
      DC-derived EV vaccines. DC-EBs are molecular snapshots of DCs in time, cell-like 
      particles with fixed stimulatory profiles for controlled immune signalling. 
      DC-EBs were produced an order of magnitude more quickly and efficiently than 
      conventional EVs and displayed stable structural integrity and antigen 
      presentation compared to live DCs. Multi-omic analysis confirmed DC-EBs are 
      majorly pure plasma membrane vesicles that are homogeneous at the single-vesicle 
      level, critical for safe and effective vaccination. Immature vs. mature molecular 
      profiles on DC-EBs exhibited molecularly modulated immune responses compared to 
      live DCs, improving remission and survival of tumor-challenged mice via 
      generation of antigen-specific T cells. For the first time, DC-EBs make their 
      case for use in vaccines and for their potential in modulating other immune 
      responses, potentially in combination with other immunotherapeutics.
FAU - Thone, Melissa N
AU  - Thone MN
AD  - Department of Chemical and Biomolecular Engineering, University of California, 
      Irvine, CA 92697, United States.
AD  - Department of Pharmaceutical Sciences, University of California, Irvine, CA 
      92697, United States.
FAU - Chung, Jee Young
AU  - Chung JY
AD  - Department of Pharmaceutical Sciences, University of California, Irvine, CA 
      92697, United States.
FAU - Ingato, Dominique
AU  - Ingato D
AD  - Department of Chemical and Biomolecular Engineering, University of California, 
      Irvine, CA 92697, United States.
FAU - Lugin, Margaret L
AU  - Lugin ML
AD  - Department of Chemical and Biomolecular Engineering, University of California, 
      Irvine, CA 92697, United States.
FAU - Kwon, Young Jik
AU  - Kwon YJ
AD  - Department of Chemical and Biomolecular Engineering, University of California, 
      Irvine, CA 92697, United States.
AD  - Department of Pharmaceutical Sciences, University of California, Irvine, CA 
      92697, United States.
AD  - Department of Molecular Biology and Biochemistry, University of California, 
      Irvine, CA 92697, United States.
AD  - Department of Biomedical Engineering, University of California, Irvine, CA 92697, 
      United States.
LA  - eng
GR  - S10 OD021718/OD/NIH HHS/United States
GR  - S10 RR025496/RR/NCRR NIH HHS/United States
GR  - T32 AI007319/AI/NIAID NIH HHS/United States
GR  - P30 CA062203/CA/NCI NIH HHS/United States
GR  - P50 GM076516/GM/NIGMS NIH HHS/United States
GR  - S10 OD010794/OD/NIH HHS/United States
PT  - Journal Article
DEP - 20220913
PL  - Germany
TA  - Adv Ther (Weinh)
JT  - Advanced therapeutics
JID - 101724632
PMC - PMC9888466
MID - NIHMS1839258
OTO - NOTNLM
OT  - Immunotherapy
OT  - cancer
OT  - dendritic cell
OT  - extracellular blebs
OT  - vaccine
COIS- Conflict of interest statement: YJK is a co-founder of Jupiter Pharmaceuticals, 
      Inc., a company based on applying extracellular blebs for drug delivery and 
      general therapeutics. The potential conflict of interest is fully disclosed to 
      and managed by the COI Oversight Committee at UC Irvine.
EDAT- 2023/02/04 06:00
MHDA- 2023/02/04 06:01
PMCR- 2024/01/01
CRDT- 2023/02/03 02:00
PHST- 2023/02/03 02:00 [entrez]
PHST- 2023/02/04 06:00 [pubmed]
PHST- 2023/02/04 06:01 [medline]
PHST- 2024/01/01 00:00 [pmc-release]
AID - 2200125 [pii]
AID - 10.1002/adtp.202200125 [doi]
PST - ppublish
SO  - Adv Ther (Weinh). 2023 Jan;6(1):2200125. doi: 10.1002/adtp.202200125. Epub 2022 
      Sep 13.